著者
Koichiro Kinugawa Yasushi Sakata Minoru Ono Shinichi Nunoda Koichi Toda Norihide Fukushima Akira Shiose Shogo Oishi Dai Yumino Teruhiko Imamura Miyoko Endo Yumiko Hori Koichi Kashiwa Kaoruko Aita Hiroyuki Kojin Yutaka Tejima Yoshiki Sawa
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
vol.85, no.10, pp.1906-1917, 2021-09-24 (Released:2021-09-24)
参考文献数
21
被引用文献数
8

Destination therapy (DT) is the indication to implant a left ventricular assist device (LVAD) in a patient with stage D heart failure who is not a candidate for heart transplantation. The implantable LVAD has been utilized in Japan since 2011 under the indication of bridge to transplant (BTT). After almost 10 year lag, DT has finally been approved and reimbursed in May 2021 in Japan. To initiate the DT program in Japan, revision of the LVAD indication from BTT is necessary. Also, in-depth discussion of caregiver issues as well as end-of-life care is indispensable. For that purpose, we assembled a DT committee of multidisciplinary members in August 2020, and started monthly discussions via web-based communication during the COVID-19 pandemic. This is a summary of the consensus reached after 6 months’ discussion, and we have included as many relevant topics as possible. Clinical application of DT has just started, and we are willing to revise this consensus to meet the forthcoming issues raised during real-world clinical experience.

言及状況

外部データベース (DOI)

Twitter (6 users, 7 posts, 25 favorites)

DTは長い間承認が待たれてきましたが、ようやくこの海外で当たり前の治療が日本でもできるようになりました。その実施要項をまとめました。ぜひご一読下さい。 By 絹川弘一郎 https://t.co/vFQtHd28v0 #circ_j https://t.co/h6p31aLzY4
DT has long been waited for approval in Japan. This policy is overwhelmingly popular in the US and Europe, and many transplant-ineligible patients are able to enjoy LVAD benefit. By Koichiro Kinugawa https://t.co/vFQtHd28v0 #circ_j https://t.co/jzA6UuDsiq

収集済み URL リスト